Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

NUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias. The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.

NUEDEXTA Important Safety Information

NUEDEXTA can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindica
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 The Female Health ... an investor conference call to discuss its operating results ... 30, 2014 on Tuesday, December 2, 2014 at 11:00 ... report its operating results earlier the same day. ... the conference call by dialing 1-877-374-8416 (international participants dial ...
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
(Date:11/24/2014)... , Nov. 24, 2014  Pifflers United ... announced the release of results of a ... device, in the self-management of fibromyalgia pain. The ... of worst pain, very significant clinically meaningful pain ... 140 group members with fibromyalgia used ActiPatch® for ...
Breaking Medicine Technology:The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... , ST. PAUL, Minn. , ... take ibuprofen may reduce their risk of developing Parkinson,s disease, according to ... Academy of Neurology ,s 62nd Annual Meeting in Toronto ... people who did not have Parkinson,s disease at the beginning of the ...
... , , CAGLIARI, Italy , Feb. ... than 4500 patients from six Italian EVEREST (European Vertebroplasty Research ... , Dr. P. Carpeggiani-Pisa, Dr. S. Masala-Roma , Dr. ... treating vertebral compression fractures (VCFs), finding that the procedure provides ...
Cached Medicine Technology:An Ibuprofen a Day Could Keep Parkinson's Disease Away 2Multi-Center Data in a Large Series of Patients Show Vertebroplasty Provides Dramatic and Lasting Pain Relief for Vertebral Compression Fractures 2Multi-Center Data in a Large Series of Patients Show Vertebroplasty Provides Dramatic and Lasting Pain Relief for Vertebral Compression Fractures 3Multi-Center Data in a Large Series of Patients Show Vertebroplasty Provides Dramatic and Lasting Pain Relief for Vertebral Compression Fractures 4
(Date:11/24/2014)... Olaparib functions as a chemical of the compound ... the first PARP inhibitors. Sufferers with BRCA1/2 strains may ... and are often immune to other types of melanoma ... exclusive weaknesses, as the tissues of melanoma have improved ... them to proceed splitting. This implies that medication which ...
(Date:11/24/2014)... SWAccessControl.com has recently released a new collection ... the company is a leading online supplier in the international ... available at discounted prices, up to 30% off. , “We ... This time, all of our items are offered at low ... so I have confidence in our fresh assortment. You will ...
(Date:11/24/2014)... 2014 SafeHandles™ announced that they will ... Ed Begley Jr, airing via Discovery Channel. Dates and ... a passive, non-invasive, replaceable, and affordable germ protective device. ... shrinkable sleeves and adhesives to promote hand hygiene in ... core of SafeHandles is the desire to make a ...
(Date:11/24/2014)... California (PRWEB) November 24, 2014 Dr. ... Diego Fertility Center, recently appeared on NBC to discuss egg ... Egg freezing has been trending in the news recently, with ... expensive procedure for women. , “[The companies] see ... who are on a career hot path.” Says Dr. Kettel. ...
(Date:11/23/2014)... 24, 2014 iFitDress.com, a well-known wedding dress ... evening gowns . They are now offered at deeply ... will last from now to Dec. 15. The main purpose ... All the company’s high quality items are ideal options for ... large sum of money. All its new mint cocktail dresses ...
Breaking Medicine News(10 mins):Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2
... effective for inoperable liver cancer. It is a year since TheraSphere was ... ... either reducing tumour size or the number of tumours. Till date, it ... cannot be treated by any other means. ,TheraSphere involves injecting ...
... given to babies with low birth weight can significantly ... die from infectious diseases. The research involved 1,154 full-term ... India, most weighing 5 1/2 pounds or less. Mothers ... months. Fifteen of the 20 who died had not ...
... starting the day with a heavy breakfast and a steaming cup ... that women who eat fried food each morning are at ... oesophageal, cancer.The best way to reduce the incidence of cancer is ... or fruit. ,Cancer of the oesophagus - the food ...
... An enzyme involved in hormone production may help explain why ... their waist have such a high risk of heart disease ... approaches to treat obesity and its complications. // ... health problems such as heart disease and diabetes, but where ...
... who use stimulants like Ritalin are not at risk ... rats suggests that stimulant treatment in childhood may blunt ... ,Many children and teens with ADHD are treated ... appear to focus patients' attention and calm behavior. But ...
... than men to suffer brain cell damage from long-term use ... be reversed if they stop taking the drug. Studies have ... MDMA, can damage nerve endings that release serotonin, a brain ... also appears to damage brain cells that transmit nerve signals. ...
Cached Medicine News:Health News:Cut down on fries 2
... Stainless steel spiral reinforced. X-ray opaque . ... Flange: The flange can be adjusted along ... of the cervical soft tissue. The lock ... is tightly connected to the shaft. Maximum ...
Fome-Cuf® tubes can breathe with the patient to provide a safe, effective, and low pressure seal throughout the ventilatory cycle....
... tracheostomy tubes are available in both neonatal and ... an uncuffed tube, but it has a cuff. ... shaft of the tube. , ,TTS™ (tight-to-shaft) ... with the insurance of a cuff, if and ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions....
Medicine Products: